122 related articles for article (PubMed ID: 11374802)
41. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Braga F; Ferraro S; Mozzi R; Dolci A; Panteghini M
Clin Biochem; 2013 Jan; 46(1-2):148-51. PubMed ID: 23000312
[TBL] [Abstract][Full Text] [Related]
42. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
Georgantzi K; Sköldenberg EG; Stridsberg M; Kogner P; Jakobson Å; Janson ET; Christofferson RHB
Pediatr Hematol Oncol; 2018 Mar; 35(2):156-165. PubMed ID: 29737901
[TBL] [Abstract][Full Text] [Related]
43. Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase.
Rasmuson T; Grankvist K; Roos G; Ljungberg B
Acta Oncol; 1999; 38(5):623-8. PubMed ID: 10427952
[TBL] [Abstract][Full Text] [Related]
44. Chromogranin A plasma concentration and expression in pancreatic islet cell tumors of dogs and cats.
Myers NC; Andrews GA; Chard-Bergstrom C
Am J Vet Res; 1997 Jun; 58(6):615-20. PubMed ID: 9185968
[TBL] [Abstract][Full Text] [Related]
45. Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases.
Lu J; Xue LY; Lu N; Zou SM; Liu XY; Wen P
Dis Esophagus; 2010 Feb; 23(2):153-9. PubMed ID: 19515193
[TBL] [Abstract][Full Text] [Related]
46. Neuroendocrine tissue-specific transcription factor, BETA2/NeuroD, in gastric carcinomas: a comparison with chromogranin A and synaptophysin expressions.
Fujii A; Kamiakito T; Takayashiki N; Fujii T; Tanaka A
Pathol Res Pract; 2003; 199(8):513-9. PubMed ID: 14533935
[TBL] [Abstract][Full Text] [Related]
47. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.
Mucci NR; Akdas G; Manely S; Rubin MA
Hum Pathol; 2000 Apr; 31(4):406-14. PubMed ID: 10821485
[TBL] [Abstract][Full Text] [Related]
48. Olfactory neuroblastoma: clinical and pathological aspects.
Lund VJ; Milroy C
Rhinology; 1993 Mar; 31(1):1-6. PubMed ID: 7686684
[TBL] [Abstract][Full Text] [Related]
49. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
50. Three cases of carcinoid in the equine nasal cavity and maxillary sinuses: histologic and immunohistochemical features.
van Maanen C; Klein WR; Dik KJ; van den Ingh TS
Vet Pathol; 1996 Jan; 33(1):92-5. PubMed ID: 8826014
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathologic and DNA cytometric analysis of carcinoid tumors of the thymus.
Goto K; Kodama T; Matsuno Y; Yokose T; Asamura H; Kamiya N; Shimosato Y
Mod Pathol; 2001 Oct; 14(10):985-94. PubMed ID: 11598168
[TBL] [Abstract][Full Text] [Related]
52. The expression of selected neuroendocrine markers and of anti-neoplastic cytokines (IL-2 and IL-12) in lung cancers.
Kasprzak A; Przewoźna M; Surdyk-Zasada J; Zabel M
Folia Morphol (Warsz); 2003 Nov; 62(4):497-9. PubMed ID: 14655151
[TBL] [Abstract][Full Text] [Related]
53. Paragangliomas of the head and neck: immunohistochemical neuroendocrine and intermediate filament typing.
Johnson TL; Zarbo RJ; Lloyd RV; Crissman JD
Mod Pathol; 1988 May; 1(3):216-23. PubMed ID: 2467285
[TBL] [Abstract][Full Text] [Related]
54. Neuroendocrine differentiation and prognosis in breast adenocarcinoma.
Miremadi A; Pinder SE; Lee AH; Bell JA; Paish EC; Wencyk P; Elston CW; Nicholson RI; Blamey RW; Robertson JF; Ellis IO
Histopathology; 2002 Mar; 40(3):215-22. PubMed ID: 11895486
[TBL] [Abstract][Full Text] [Related]
55. Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Dittadi R; Gion M
Clin Biochem; 2013 Aug; 46(12):1145. PubMed ID: 23608355
[No Abstract] [Full Text] [Related]
56. [Synaptophysin, chromogranin A and neuron-specific enolase as tumor markers in neuroendocrine tumors of the gastrointestinal tract and lung. An immunohistochemical study].
Eberlein-Gonska M; Wiedenmann B; Waldherr R
Pathologe; 1989 Jul; 10(4):228-33. PubMed ID: 2549534
[No Abstract] [Full Text] [Related]
57. Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer.
Grabowski P; Schindler I; Anagnostopoulos I; Foss HD; Riecken EO; Mansmann U; Stein H; Berger G; Buhr HJ; Scherübl H
Eur J Gastroenterol Hepatol; 2001 Apr; 13(4):405-11. PubMed ID: 11338071
[TBL] [Abstract][Full Text] [Related]
58. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study.
Slodkowska J; Zych J; Szturmowicz M; Demkow U; Rowinska-Zakrzewska E; Roszkowski-Sliz K
Int J Biol Markers; 2005; 20(4):217-26. PubMed ID: 16398403
[TBL] [Abstract][Full Text] [Related]
59. Middle ear adenomatous tumor with a predominant neuroendocrine component.
Paraskevakou H; Lazaris AC; Kandiloros DC; Papadimitriou K; Adamopoulos G; Davaris PS
Pathology; 1999 Aug; 31(3):284-7. PubMed ID: 10503278
[TBL] [Abstract][Full Text] [Related]
60. Comparative evaluation of neural tissue antigens--neurofilament protein (NF), peripherin (PRP), S100B protein (S100B), neuron-specific enolase (NSE) and chromogranin-A (CgA)--in both normal and inflamed human mature dental pulp.
Dourou V; Lyroudia K; Karayannopoulou G; Papadimitriou C; Molyvdas I
Acta Histochem; 2006; 108(5):343-50. PubMed ID: 16919707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
